Skip to main navigation Skip to search Skip to main content

Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis

  • David O. Azorsa
  • , David W. Lee
  • , Daniel H. Wai
  • , Ranjan Bista
  • , Apurvi R. Patel
  • , Eiman Aleem
  • , Michael M. Henry
  • , Robert J. Arceci
  • Phoenix Children's Hospital
  • University of Arizona
  • Institute of Molecular Medicine
  • Department of Child Health
  • Alexandria University

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Patients with Langerhans cell histiocytosis (LCH) harbor BRAF V600E and activating mutations of MAP2K1/MEK1 in 50% and 25% of cases, respectively. We evaluated a patient with treatment-refractory LCH for mutations in the RAS-RAF-MEK-ERK pathway and identified a novel mutation in the MAP2K1 gene resulting in a p.L98_K104 > Q deletion and predicted to be auto-activating. During treatment with the MEK inhibitor trametinib, the patient's disease showed significant progression. In vitro characterization of the MAP2K1 p.L98_K104 > Q deletion confirmed its effect on cellular activation of the ERK pathway and drug resistance.

Original languageEnglish
Article numbere27237
Pages (from-to)e27237-e27237
JournalPediatric Blood and Cancer
Volume65
Issue number9
DOIs
Publication statusPublished - 16 May 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 Wiley Periodicals, Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Langerhans cell histiocytosis
  • MAP2K1
  • mutation

Fingerprint

Dive into the research topics of 'Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis'. Together they form a unique fingerprint.

Cite this